Nyxoah: Label Expansion Set To Unlock A Monopoly In A Billion Dollar Market.

Stephen Tobin Investing Group Leader Follow Summary Nyxoah is entering its first growth stage, targeting the OSA device market with the Genio implant, and is currently undervalued relative to growth prospects. Genio could secure a monopoly on 30% of the OSA market by 2027, pending FDA label extension for Complete Concentric Collapse (CCC) patients, supported by strong clinical trial results. NYXH projects €36 million revenue for 2026, up 260% YoY, with visibility supported by rapid growth in trained surgeons, active accounts, and prior authorizations. My discounted cash flow model yields a €9.76 ($11) price target—700% upside—though risks include coding delays, management turnover, and ongoing patent litigation. Looking for a portfolio of ideas like this one? Members of Strategic Wave Investments get exclusive access to our subscriber-only portfolios. Learn More » We Are/DigitalVision via Getty Images Nyxoah ( NYXH ) is a small $133 million market cap company with a medical device approved for use in Obstructive Sleep Apnea [OSA]. OSA is a chronic condition where the muscles in the throat relax This article was written by Stephen Tobin 19.03K Followers Follow I am a full-time investor and analyst with over 20 years of market experience, specializing in the "Deep Tech" small-cap frontier. My career began with Bank of America in the 1980s, and I hold an MBA with professional qualifications in accounting and company valuation. My approach to the markets is a blend of academic rigor and "scar tissue" experience. I am the third generation of investors in my family; my grandfather survived the crash of 1929, and my father navigated the 1970s oil crisis. Having traded through the Dot Com bubble and the 2008 Credit Crisis, I’ve learned the hard way that success is built on a simple, disciplined mandate: identify winners, cut losses early, and let the waves of disruption run. This philosophy has evolved into Strategic Waves Capital Management, a boutique firm I run alongside my partner, a qualified lawyer. Together, we use Financial and Mathematical Theory combined with primary research—including executive and academic interviews—to filter the "hype" from the real commercial breakthroughs in sectors like Quantum Sensing, Biotech, and the electrification of everything. Today, I lead the Strategic Wave Investments group here on Seeking Alpha. Providing: Total Transparency: We report only on real-money trading in live accounts. Members access our Dual Strategies: From our high-conviction longer-term portfolio to our tactical "$250-to-$100K" trading challenge. Whether we are tracking the next generation of disruptive technology or managing high-beta volatility, our goal is to provide the institutional-grade clarity you need to invest with conviction. Analyst’s Disclosure: I/we have a beneficial long position in the shares of NYXH either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.